Charles M Conway
Overview
Explore the profile of Charles M Conway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dzierba C, Dasgupta B, Karageorge G, Kostich W, Hamman B, Allen J, et al.
Med Chem Res
. 2023 Jun;
:1-7.
PMID: 37362320
Graphical Abstract:
2.
Luo G, Chen L, Kostich W, Hamman B, Allen J, Easton A, et al.
J Med Chem
. 2022 Mar;
65(6):4534-4564.
PMID: 35261239
Recent mouse knockout studies identified adapter protein-2-associated kinase 1 (AAK1) as a viable target for treating neuropathic pain. BMS-986176/LX-9211 (), as a highly selective, CNS-penetrable, and potent AAK1 inhibitor, has...
3.
Luo G, Chen L, Kostich W, Hamman B, Allen J, Easton A, et al.
J Med Chem
. 2022 Mar;
65(6):4457-4480.
PMID: 35257579
Recent mouse knockout studies identified adapter protein-2 associated kinase 1 (AAK1) as a viable target for treating neuropathic pain. Potent small-molecule inhibitors of AAK1 have been identified and show efficacy...
4.
Luo G, Jiang X, Chen L, Conway C, Gulianello M, Kostich W, et al.
Bioorg Med Chem Lett
. 2021 May;
43:128077.
PMID: 33932522
In our efforts to identify orally bioavailable CGRP receptor antagonists, we previously discovered a novel series of orally available azepinone derivatives that unfortunately also exhibited the unwanted property of potent...
5.
Croop R, Lipton R, Kudrow D, Stock D, Kamen L, Conway C, et al.
Lancet
. 2020 Dec;
397(10268):51-60.
PMID: 33338437
Background: Rimegepant is a calcitonin gene-related peptide receptor antagonist that has shown efficacy and safety in the acute treatment of migraine. We aimed to compare the efficacy of rimegepant with...
6.
Mercer S, Chaturvedula P, Conway C, Cook D, Davis C, Pin S, et al.
Bioorg Med Chem Lett
. 2020 Oct;
31:127624.
PMID: 33096162
Calcitonin gene-related peptide (CGRP) receptor antagonists have been shown clinically to be effective treatments for migraine. Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP K ...
7.
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry A, et al.
Headache
. 2020 Aug;
60(8):1734-1742.
PMID: 32799325
Objective: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) ligand or receptor (CGRP...
8.
Dubowchik G, Conway C, Xin A
J Med Chem
. 2020 Feb;
63(13):6600-6623.
PMID: 32058712
The pivotal role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology was identified over 30 years ago, but the successful clinical development of targeted therapies has only recently been realized....
9.
Mullin K, Kudrow D, Croop R, Lovegren M, Conway C, Coric V, et al.
Neurology
. 2020 Jan;
94(20):e2121-e2125.
PMID: 31932515
Objective: To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to...
10.
Croop R, Goadsby P, Stock D, Conway C, Forshaw M, Stock E, et al.
Lancet
. 2019 Jul;
394(10200):737-745.
PMID: 31311674
Background: Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was...